ScholarIQanswers from OpenAlex & ORCID
Elizabeth A. Maher
ResearcherPublications, citations & collaboration network
Elizabeth A. Maher is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Elizabeth A. Maher have?
ScholarIQindexed works
Elizabeth A. Maher has 220 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Elizabeth A. Maher have?
ScholarIQcitation count
Elizabeth A. Maher has 17,187 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Elizabeth A. Maher?
ScholarIQh-index
Elizabeth A. Maher has an h-index of 50 in OpenAlex.
What is the i10-index of Elizabeth A. Maher?
ScholarIQi10-index
Elizabeth A. Maher has an i10-index of 100 in OpenAlex.
What is the ORCID of Elizabeth A. Maher?
ScholarIQorcid
The ORCID for Elizabeth A. Maher is on the source record.
What is the OpenAlex record for Elizabeth A. Maher?
ScholarIQopenalex
The OpenAlex for Elizabeth A. Maher is on the source record.
What are the most-cited papers on Elizabeth A. Maher?
ScholarIQmost cited works
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim, Craig H. Mermel, Dale Porter, Guo Wei, Soumya Raychaudhuri, Jerry Donovan, Jordi Barretina, Jesse S. Boehm, Jennifer Dobson, Mitsuyoshi Urashima, Kevin T. Mc Henry, Reid M. Pinchback, Azra H. Ligon, Yoon‐Jae Cho, Leila Haery, Heidi Greulich, Michael Reich, Wendy Winckler, Michael S. Lawrence, Barbara A. Weir, Kumiko Tanaka, Derek Y. Chiang, Adam J. Bass, Alice Loo, Carter Hoffman, John R. Prensner, Ted Liefeld, Qing Gao, Derek Yecies, Sabina Signoretti, Elizabeth A. Maher, Frederic J. Kaye, Hidefumi Sasaki, Joel E. Tepper, Jonathan A. Fletcher, Josep Tabernero, José Baselga, Ming‐Sound Tsao, Francesca Demichelis, Mark A. Rubin, Pasi A. Jänne, Mark J. Daly, Carmelo Nucera, Ross L. Levine, Benjamin L. Ebert, Stacey Gabriel, Anil K. Rustgi, Cristina R. Antonescu, Marc Ladanyi, Anthony Letai, Levi A. Garraway, Massimo Loda, David G. Beer, Lawrence D. True, Aikou Okamoto, Scott L. Pomeroy, Samuel Singer, Todd R. Golub, Eric S. Lander, Gad Getz, William R. Sellers, Matthew Meyerson
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, Mehdi Touat, Katherine B. Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust‐Katz, Liam Welsh, Warren Mason, François Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F. Hottinger, Yoshiki Arakawa, Juan Manuel Sepúlveda-Sánchez, Wolfgang Wick, Riccardo Soffietti, James Perry, Pierre Giglio, Macarena de la Fuente, Elizabeth A. Maher, Steven Schoenfeld, Dan Zhao, Shuchi S. Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen, Timothy F. Cloughesy
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Ingo K. Mellinghoff, Marta Peñas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Jankú, Gregory M. Coté, Macarena I. de la Fuente, Jennifer Clarke, Benjamin M. Ellingson, Saewon Chun, Robert J. Young, Hua Liu, Sung Choe, Min Lu, Kha Le, Islam Hassan, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Ingo K. Mellinghoff, Min Lu, Patrick Y. Wen, Jennie Taylor, Elizabeth A. Maher, Isabel Arrillaga‐Romany, Katherine B. Peters, Benjamin M. Ellingson, Marc K. Rosenblum, Saewon Chun, Kha Le, Anna M. Tassinari, Sung Choe, Youssef Toubouti, Steven Schoenfeld, Shuchi S. Pandya, Islam Hassan, Lori Steelman, Jennifer Clarke, Timothy F. Cloughesy